ANTX
AN2 Therapeutics·NASDAQ
--
--(--)
--
--(--)
ANTX fundamentals
AN2 Therapeutics (ANTX) released its earnings on Aug 12, 2025: revenue was 0 (YoY --), met estimates; EPS was -0.21 (YoY +56.25%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-0.21
+56.25%
Report date
Aug 12, 2025
EPS
Actual | -2.98 | -0.53 | -0.59 | -0.61 | -0.79 | -0.81 | -0.65 | -0.57 | -0.56 | -0.48 | -0.43 | -0.25 | -0.35 | -0.21 |
Forecast | -0.93 | -1.5375 | -0.5925 | -0.6325 | -0.6575 | -0.8525 | -0.6475 | -0.736 | -0.62 | -0.606 | -0.45 | -0.27 | -0.265 | -0.335 |
Surprise | -220.43% | +65.53% | +0.42% | +3.56% | -20.15% | +4.99% | -0.39% | +22.55% | +9.68% | +20.79% | +4.44% | +7.41% | -32.08% | +37.31% |
Revenue
Actual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Forecast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What is the revenue and EPS growth rate for AN2 Therapeutics year over year?What guidance did AN2 Therapeutics's management provide for the next earnings period?What does AN2 Therapeutics do and what are its main business segments?What were the key takeaways from AN2 Therapeutics’s earnings call?What is AN2 Therapeutics's gross profit margin?What is AN2 Therapeutics's latest dividend and current dividend yield?Did AN2 Therapeutics beat or miss consensus estimates last quarter?What factors drove the changes in AN2 Therapeutics's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
